Climb Bio, Inc. (NASDAQ:CLYM – Get Free Report)’s share price traded down 2.4% on Monday . The stock traded as low as $1.23 and last traded at $1.23. 61,251 shares traded hands during trading, a decline of 81% from the average session volume of 328,917 shares. The stock had previously closed at $1.26.
Climb Bio Price Performance
The firm has a 50 day simple moving average of $1.33. The company has a market cap of $82.99 million, a PE ratio of -0.58 and a beta of -0.10.
Climb Bio (NASDAQ:CLYM – Get Free Report) last posted its quarterly earnings data on Tuesday, March 25th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.02. Analysts anticipate that Climb Bio, Inc. will post -1.57 earnings per share for the current fiscal year.
About Climb Bio
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
Further Reading
- Five stocks we like better than Climb Bio
- Market Cap Calculator: How to Calculate Market Cap
- AST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer Stock
- What Are Dividend Challengers?
- Why Call Option Traders Are Targeting This Dividend ETF Now
- Investing In Preferred Stock vs. Common Stock
- Is Alphabet Misunderstood? Here’s Why the Bulls Are Buying
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.
